Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence

Introduction Vitamin D has long been known for its immune-modulating effects, next to its function in calcium metabolism. As a consequence, poor vitamin D status has been associated with many diseases including multiple sclerosis (MS). Epidemiological studies suggest an association between a poor vitamin D status and development of MS and a poor vitamin D status is associated with more relapses and faster progression after patients are diagnosed with MS. Area's covered The aim of the authors was to review the role of vitamin D supplementation in the treatment of MS. Pubmed was used to review literature with a focus of vitamin D supplementation trials and meta-analyses in MS. Expert opinion There is no solid evidence to support the application of vitamin D therapy, based on current available supplementation trials, although there are some promising results in the clinically isolated syndrome (CIS) patients and young MS patients early after initial diagnosis. The authors recommend further larger clinical trials with selected patient groups, preferable CIS patients and young patients at the time of diagnosis, using vitamin D-3 supplements to reach a 100 nmol/l level, to further investigate the effects of vitamin D supplementation in MS.

Automated summary

There is currently no solid evidence to support the use of vitamin D therapy in treating MS, although there are promising results in clinically isolated syndrome (CIS) patients and young MS patients early after diagnosis. Further large-scale clinical trials are recommended to investigate the effects of vitamin D supplementation in MS, particularly in selected patient groups such as CIS patients and young patients at the time of diagnosis, aiming to reach a level of 100 nmol/l with vitamin D-3 supplements.